vs

Side-by-side financial comparison of FirstCash Holdings, Inc. (FCFS) and PHIBRO ANIMAL HEALTH CORP (PAHC). Click either name above to swap in a different company.

FirstCash Holdings, Inc. is the larger business by last-quarter revenue ($501.3M vs $373.9M, roughly 1.3× PHIBRO ANIMAL HEALTH CORP). FirstCash Holdings, Inc. runs the higher net margin — 20.8% vs 7.3%, a 13.4% gap on every dollar of revenue. On growth, FirstCash Holdings, Inc. posted the faster year-over-year revenue change (21.2% vs 20.9%). Over the past eight quarters, PHIBRO ANIMAL HEALTH CORP's revenue compounded faster (19.2% CAGR vs 16.9%).

FirstCash Holdings, Inc. is an American pawnshop company headquartered in Fort Worth, Texas which operates retail pawn stores in the U.S. and Latin America. It is a publicly traded company listed on the Nasdaq stock exchange.

Phibro Animal Health Corporation is an American animal health and mineral nutrition company. Its products include antibacterials, anticoccidials, anthelmintics, as well as animal nutrition and vaccines for livestock. The company operates through three segments Mineral Nutrition, Performance Materials, and Animal Health, from which most of its revenue is derived. The company operates in the United States, Latin America, Canada, Europe, Middle East, Africa, and Asia-Pacific. It is incorporated ...

FCFS vs PAHC — Head-to-Head

Bigger by revenue
FCFS
FCFS
1.3× larger
FCFS
$501.3M
$373.9M
PAHC
Growing faster (revenue YoY)
FCFS
FCFS
+0.3% gap
FCFS
21.2%
20.9%
PAHC
Higher net margin
FCFS
FCFS
13.4% more per $
FCFS
20.8%
7.3%
PAHC
Faster 2-yr revenue CAGR
PAHC
PAHC
Annualised
PAHC
19.2%
16.9%
FCFS

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
FCFS
FCFS
PAHC
PAHC
Revenue
$501.3M
$373.9M
Net Profit
$104.2M
$27.5M
Gross Margin
35.5%
Operating Margin
28.5%
13.5%
Net Margin
20.8%
7.3%
Revenue YoY
21.2%
20.9%
Net Profit YoY
24.7%
762.1%
EPS (diluted)
$2.35
$0.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FCFS
FCFS
PAHC
PAHC
Q4 25
$501.3M
$373.9M
Q3 25
$411.0M
$363.9M
Q2 25
$385.1M
$378.7M
Q1 25
$371.1M
$347.8M
Q4 24
$413.7M
$309.3M
Q3 24
$363.1M
$260.4M
Q2 24
$363.5M
$273.2M
Q1 24
$366.8M
$263.2M
Net Profit
FCFS
FCFS
PAHC
PAHC
Q4 25
$104.2M
$27.5M
Q3 25
$82.8M
$26.5M
Q2 25
$59.8M
$17.2M
Q1 25
$83.6M
$20.9M
Q4 24
$83.5M
$3.2M
Q3 24
$64.8M
$7.0M
Q2 24
$49.1M
$752.0K
Q1 24
$61.4M
$8.4M
Gross Margin
FCFS
FCFS
PAHC
PAHC
Q4 25
35.5%
Q3 25
32.9%
Q2 25
29.0%
Q1 25
30.1%
Q4 24
32.9%
Q3 24
32.1%
Q2 24
31.9%
Q1 24
30.2%
Operating Margin
FCFS
FCFS
PAHC
PAHC
Q4 25
28.5%
13.5%
Q3 25
27.4%
14.1%
Q2 25
21.1%
8.9%
Q1 25
30.0%
9.6%
Q4 24
26.5%
8.3%
Q3 24
23.5%
6.8%
Q2 24
18.2%
6.7%
Q1 24
22.3%
7.6%
Net Margin
FCFS
FCFS
PAHC
PAHC
Q4 25
20.8%
7.3%
Q3 25
20.1%
7.3%
Q2 25
15.5%
4.5%
Q1 25
22.5%
6.0%
Q4 24
20.2%
1.0%
Q3 24
17.9%
2.7%
Q2 24
13.5%
0.3%
Q1 24
16.7%
3.2%
EPS (diluted)
FCFS
FCFS
PAHC
PAHC
Q4 25
$2.35
$0.67
Q3 25
$1.86
$0.65
Q2 25
$1.34
$0.43
Q1 25
$1.87
$0.51
Q4 24
$1.86
$0.08
Q3 24
$1.44
$0.17
Q2 24
$1.08
$0.02
Q1 24
$1.35
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FCFS
FCFS
PAHC
PAHC
Cash + ST InvestmentsLiquidity on hand
$125.2M
$74.5M
Total DebtLower is stronger
$2.2B
$624.2M
Stockholders' EquityBook value
$2.3B
$332.4M
Total Assets
$5.3B
$1.4B
Debt / EquityLower = less leverage
0.98×
1.88×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FCFS
FCFS
PAHC
PAHC
Q4 25
$125.2M
$74.5M
Q3 25
$130.2M
$85.3M
Q2 25
$101.5M
$77.0M
Q1 25
$146.0M
$70.4M
Q4 24
$175.1M
$67.1M
Q3 24
$106.3M
$89.8M
Q2 24
$113.7M
$114.6M
Q1 24
$135.1M
$98.7M
Total Debt
FCFS
FCFS
PAHC
PAHC
Q4 25
$2.2B
$624.2M
Q3 25
$2.2B
$628.0M
Q2 25
$1.7B
$631.7M
Q1 25
$1.7B
$635.4M
Q4 24
$1.7B
$639.1M
Q3 24
$1.7B
$295.2M
Q2 24
$1.7B
$312.1M
Q1 24
$1.5B
Stockholders' Equity
FCFS
FCFS
PAHC
PAHC
Q4 25
$2.3B
$332.4M
Q3 25
$2.2B
$311.7M
Q2 25
$2.1B
$285.7M
Q1 25
$2.1B
$266.0M
Q4 24
$2.1B
$246.8M
Q3 24
$2.0B
$258.5M
Q2 24
$2.0B
$256.6M
Q1 24
$2.0B
$270.1M
Total Assets
FCFS
FCFS
PAHC
PAHC
Q4 25
$5.3B
$1.4B
Q3 25
$5.2B
$1.4B
Q2 25
$4.5B
$1.4B
Q1 25
$4.4B
$1.3B
Q4 24
$4.5B
$1.3B
Q3 24
$4.4B
$966.3M
Q2 24
$4.3B
$982.2M
Q1 24
$4.2B
$979.0M
Debt / Equity
FCFS
FCFS
PAHC
PAHC
Q4 25
0.98×
1.88×
Q3 25
1.01×
2.01×
Q2 25
0.79×
2.21×
Q1 25
0.83×
2.39×
Q4 24
0.85×
2.59×
Q3 24
0.87×
1.14×
Q2 24
0.85×
1.22×
Q1 24
0.75×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FCFS
FCFS
PAHC
PAHC
Operating Cash FlowLast quarter
$206.6M
$19.4M
Free Cash FlowOCF − Capex
$8.3M
FCF MarginFCF / Revenue
2.2%
Capex IntensityCapex / Revenue
3.0%
Cash ConversionOCF / Net Profit
1.98×
0.70×
TTM Free Cash FlowTrailing 4 quarters
$47.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FCFS
FCFS
PAHC
PAHC
Q4 25
$206.6M
$19.4M
Q3 25
$135.8M
$9.3M
Q2 25
$116.9M
$21.3M
Q1 25
$126.6M
$43.2M
Q4 24
$198.1M
$3.1M
Q3 24
$113.1M
$12.6M
Q2 24
$106.2M
$28.4M
Q1 24
$122.5M
$11.4M
Free Cash Flow
FCFS
FCFS
PAHC
PAHC
Q4 25
$8.3M
Q3 25
$-4.5M
Q2 25
$8.1M
Q1 25
$35.4M
Q4 24
$-4.7M
Q3 24
$3.0M
Q2 24
$15.4M
Q1 24
$1.7M
FCF Margin
FCFS
FCFS
PAHC
PAHC
Q4 25
2.2%
Q3 25
-1.2%
Q2 25
2.1%
Q1 25
10.2%
Q4 24
-1.5%
Q3 24
1.2%
Q2 24
5.6%
Q1 24
0.6%
Capex Intensity
FCFS
FCFS
PAHC
PAHC
Q4 25
3.0%
Q3 25
3.8%
Q2 25
3.5%
Q1 25
2.2%
Q4 24
2.5%
Q3 24
3.7%
Q2 24
4.8%
Q1 24
3.7%
Cash Conversion
FCFS
FCFS
PAHC
PAHC
Q4 25
1.98×
0.70×
Q3 25
1.64×
0.35×
Q2 25
1.95×
1.24×
Q1 25
1.51×
2.07×
Q4 24
2.37×
0.97×
Q3 24
1.74×
1.81×
Q2 24
2.16×
37.80×
Q1 24
2.00×
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FCFS
FCFS

US Pawn Segment$292.2M58%
Retail POS Payment Solutions$209.8M42%

PAHC
PAHC

Medicated Feed Additives And Others$202.1M54%
Mineral Nutrition$68.9M18%
Nutritional Specialties$50.2M13%
Vaccines$37.6M10%
Performance Products$15.0M4%

Related Comparisons